Furthermore, our results support that the statins targeting HMG-CoA reductase (HMGCR) might be effective cancer therapeutics in tumors with high tyrosine metabolism and/or low heparan sulfate glycosaminoglycan biosynthesis. Here, HMGCR is linked to cancer.